[HTML] springer.comFull View

[HTML][HTML] Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular cancer, 2021 - Springer
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …
被引用次数：54 相关文章
[HTML] biomedcentral.com

[HTML][HTML] Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - molecular-cancer.biomedcentral …
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …
[HTML] nih.gov

[HTML][HTML] Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - ncbi.nlm.nih.gov
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - search.ebscohost.com
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - europepmc.org
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - go.gale.com
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - utsouthwestern.elsevierpure.com
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - search.proquest.com
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular cancer, 2021 - pubmed.ncbi.nlm.nih.gov
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS,
NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis …

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

D Tang, G Kroemer, R Kang - Molecular Cancer, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Across a broad range of human cancers, gain-
of-function mutations in< jats: italic> RAS</jats: italic> genes (< jats: italic> HRAS</jats …